Form 4 Tracker
David Charles Lubner

Director · 6 filings · Latest: Aug 5, 2026

Arcellx, Inc.
Braveheart Bio, Inc.
CRESCENT BIOPHARMA, INC.
Dyne Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
BRVE
David Charles LubnerDirectorAug 7, 2026
Purchase
$18.0055,555$1000.0K55,555
ACLX
David Charles LubnerDirectorJan 20, 2026
Sale
$75.006,000$450.0K21,659
ACLX
David Charles LubnerDirectorJan 20, 2026
Option Exercise
$6.286,000$37.7K27,659
ACLX
DAVID LUBNERJan 20, 2026
Proposed Sale
$68.9415,000$1.0M